TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01710540

Intervention type: OTHER
Group type: OTHER
Intervention: Metformin GSK 850mg
Description: EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION

Intervention type: OTHER
Group type: OTHER
Intervention: Metformin GSK 850mg
Description: EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION

Intervention type: OTHER
Group type: OTHER
Intervention: Gluocophage 850mg
Description: EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION

Intervention type: OTHER
Group type: OTHER
Intervention: Gluocophage 850mg
Description: EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
Study: NCT00693082

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Description: 1 tablespoon a day for first three days, increasing to two tablespoons a day for the next three days. On the 7th day start with 3 tablespoons per day and maintain dose throughout the duration of the study (11 weeks).
Study: NCT04432727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexitouch Plus with Cellular Connectivity (FT-CC)
Description: Daily use of FT-CC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexitouch Plus with Cellular Connectivity (FT-CC)
Description: Daily use of FT-CC
Study: NCT02697344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-Gossypol Acetic Acid
Description: Given PO
Study: NCT03347292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib(Stivarga, BAY73-4506)
Description: Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib(Stivarga, BAY73-4506)
Description: Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg i.v.(Intravenous(ly)) every 3 weeks (Q3W). This dose will not be escalated or deescalated and the dosing schedule will not be changed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg i.v.(Intravenous(ly)) every 3 weeks (Q3W). This dose will not be escalated or deescalated and the dosing schedule will not be changed
Study: NCT03543787

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Health IT and Peer Support Intervention
Description: Health IT will support referral system by establishing 1) communication between healthcare providers and peer navigators 2) decision support for clinician to facilitate appropriate referrals 3) tracking of referred patients real-time 4) dashboards to monitor key evaluation metrics.~Peer Support intervention: peer navigators at each level of the referral network will ensure 1) referral adherence by link clinicians and patients 2) health system navigation 3) psychosocial support: leverage their shared disease experience to help patients overcome barriers to health seeking behaviour.
Study: NCT03553992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POP-6:
Description: 90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to SGM young adults~Drug: nicotine patch 14-day supply of nicotine patch

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSP-6:
Description: 90 days of Facebook messaging, weekly live sessions targeting tobacco use~Drug: nicotine patch 14-day supply of nicotine patch
Study: NCT03118661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: For Step 2: Structured treatment interruption
Description: -Accepted tool in the evaluation of immunological interventions, gene therapy, or therapeutic vaccines for the treatment of HIV infection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: -Screening, entry for Step 1, Step 1 visit 2, entry for Step 2, weekly, week 16, monthly through week 52, week 52, quarterly through year 5, year 5, and viral relapse
Study: NCT03649308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: An immediate mobilization and negative pressure wound therapy (PICO) initiated after surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Traditional treatment with conventional wound dressing and 5 days of immobilization after surgery.
Study: NCT01429025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: PO
Study: NCT03393247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab and azathioprine combination at week 0
Description: All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Experimental group will receive azathioprine at week 0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab and azathioprine combination at week 14
Description: All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Control group will receive azathioprine at week 14.
Study: NCT00740935

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rotateq vaccine
Description: Vaccination against rotavirus~Three oral doses (2 mL) between 6 to 26 weeks of life with at least 4 weeks between each dose.
Study: NCT04110665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 100 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam 20 MG/ML
Description: 120 mg for 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Tablet 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Tablet 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 20mg
Description: release
Study: NCT04682119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT04321135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Lifestyle Program Intervention
Description: The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly.They will also receive a participant informational binder (wellness guide) with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Guided Lifestyle Program (Control Arm)
Description: In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging
Study: NCT02537158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE group patients will accept TACE therapy once at a month after resection.
Study: NCT04385693

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Pulpotomy using bioactive bioceramic cement of 1.5 mm layer of a newly FDA approved calcium-based silicate cement (Nusmile NeoPutty) will be placed on the pulp chamber floor and canals' orifices for pulp and root therapy. Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health.This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, complete caries removal and then access to the pulp chamber using drills.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction and placement of space maintainer
Description: If during the pulpotomy procedure, hemostasis is not obtainable, or signs of advanced pulp degeneration such as dark and limited or no bleeding from canals, the pulp will be diagnosed as chronically inflamed or necrotic, and tooth will be extracted. As part of the standard of care after extractions of primary molars, space maintenance will be assessed, and a space maintainer fabricated if indicated. Extracted teeth will serve as controls, and information regarding the need or not of space maintenance.
Study: NCT01528202

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cherry juice
Description: 30 mLs preceding morning meal and 30 mLs preceding evening meal each day for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fruit juice cordial
Description: fruit flavoured juice concentrate
Study: NCT04854447

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-Vision Spectacles
Description: Spectacle correction for myopia treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-Vision Spectacles
Description: Spectacle correction for myopia treatment
Study: NCT06131476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blink® Tears eye drops
Description: Control Drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blink® Tears eye drops
Description: Control Drops
Study: NCT01254279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABAZITAXEL
Description: Pharmaceutical form: Concentrate For Solution For Infusion Route of administration: Intravenous
Study: NCT05250661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqueous propolis extract
Description: The patients gargled 4 times a day after meals and 5 ml each time. Patients were instructed to keep the propolis solution in their mouth for one minute, to touch all structures in the mouth, and not to eat or drink anything orally for one hour after spitting.
Study: NCT01486199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absorptive clearance scan
Description: Subjects will inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m-sulfur colloid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absorptive clearance scan
Description: Subjects will inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m-sulfur colloid.
Study: NCT00820755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab plus Platinum-based Doublet Chemotherapy
Description: Single first dose of cetuximab 400 mg/m\^2 infusion will be administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m\^2 intravenous infusion over 60 min q1w with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy will be administered as intravenous infusion as per study center included: vinorelbine 25 mg/m\^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m\^2 on D1; or gemcitabine 1250 mg/m\^2 on D1 and D8+cisplatin 75 mg/m\^2 on D1; or gemcitabine 1000 mg/m\^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 milligram\*hour/milliliter (mg\*hr/mL) on D1; or Docetaxel 75 mg/m\^2 on D1+cisplatin 75 mg/m\^2 on D1; or paclitaxel 175 mg/m\^2 on D1+cisplatin 80 mg/m\^2 on D1; or paclitaxel 200 mg/m\^2 on D1+carboplatin at dose to reach AUC6 mg\*hr/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab 500 mg/m^2
Description: Subjects who will be free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 500 mg/m\^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab 250 mg/m^2
Description: Subjects who will free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 250 mg/m\^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.
Study: NCT01092845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845 / matched placebo
Description: PF-04457845 4 mg tablet once daily / matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845 / matched placebo
Description: PF-04457845 4 mg tablet once daily / matched placebo
Study: NCT03694925

Intervention type: DIAGNOSTIC_TEST
Intervention: Calprotectin test
Description: Calprotectin will be measured both by ELISA and point of care test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Calprotectin test
Description: Calprotectin will be measured both by ELISA and point of care test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Calprotectin test
Description: Calprotectin will be measured both by ELISA and point of care test.
Study: NCT01422239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored treatment
Description: 8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes tailored to the perceived risks of quitting most strongly held by each participant. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: 8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes focused on the benefits of quitting smoking. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
Study: NCT02624037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Dosage Precision IFX Dashboard
Description: Pharmacokinetic Dashboard Recommended Dosage and Dosing Frequency of Infliximab
Study: NCT01638780

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A placebo will given for 30 days, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol
Description: resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
Study: NCT00717600

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1
Description: 2x10\^9 cfu of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 administered daily via a single orally ingested freeze-dried capsule.
Study: NCT02924662

Intervention type: OTHER
Intervention: There is no intervention.
Study: NCT04429126

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure
Description: Two types acupressure interventions, 5-point and 2-point acupressure groups, will be conducted in the current study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Two types acupressure interventions, 5-point and 2-point acupressure groups, will be conducted in the current study.
Study: NCT00837785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012
Description: 240 mg (two 120 mg capsules) orally three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012
Description: 240 mg (two 120 mg capsules) orally twice a day
Study: NCT02282592

Intervention type: OTHER
Intervention: Observation about the presence of metabolic syndrome

Intervention type: OTHER
Intervention: Observation about the presence of metabolic syndrome
Study: NCT06131476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational lipid eye drops
Description: Test Drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational lipid eye drops
Description: Test Drops
Study: NCT05195697

Intervention type: OTHER
Intervention: Observational study of different treatments and time to treatment
Description: Different treatment based on the clinical decision

Intervention type: OTHER
Intervention: Observational study of different treatments and time to treatment
Description: Different treatment based on the clinical decision

Intervention type: OTHER
Intervention: Observational study of different treatments and time to treatment
Description: Different treatment based on the clinical decision

Intervention type: OTHER
Intervention: Observational study of different treatments and time to treatment
Description: Different treatment based on the clinical decision

Intervention type: OTHER
Intervention: Observational study of different treatments and time to treatment
Description: Different treatment based on the clinical decision

Intervention type: OTHER
Intervention: Observational study of different treatments and time to treatment
Description: Different treatment based on the clinical decision

Intervention type: OTHER
Intervention: Observational study of different treatments and time to treatment
Description: Different treatment based on the clinical decision

Intervention type: OTHER
Intervention: Observational study of different treatments and time to treatment
Description: Different treatment based on the clinical decision

Intervention type: OTHER
Intervention: Observational study of different treatments and time to treatment
Description: Different treatment based on the clinical decision

Intervention type: OTHER
Intervention: Observational study of different treatments and time to treatment
Description: Different treatment based on the clinical decision
Study: NCT02744157

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Longterm effects after a structured lifestyle program
Description: present study was to describe a structured intervention to reduce cardiovascular risk in a clinical setting and to study the effects of the program on lifestyle habits and quality of life in individuals at risk after six months and one year.
Study: NCT03915873

Intervention type: DIAGNOSTIC_TEST
Intervention: The von Willebrand Antigen level
Description: blood sample
Study: NCT04927728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Practice
Description: MP is the cognitive rehearsal of a motor task without physical movement, with the intent to improve motor performance. Mental practice can be completed via audio or video recording, visual prompts, written instructions, self-initiated or recorded pictures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Practice
Description: MP is the cognitive rehearsal of a motor task without physical movement, with the intent to improve motor performance. Mental practice can be completed via audio or video recording, visual prompts, written instructions, self-initiated or recorded pictures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive-Task Practice
Description: Repetitive-Task Practice is the repetitive rehearsal of a motor task with the intent to improve motor performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Therapy
Description: Traditional therapy includes traditional interventions completed in occupational therapy for patients following a stroke. These interventions include but are not limited to, range of motion, weight-bearing, massage, modalities, self-care training, and transfer training.
Study: NCT02642094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Low dose of rapamycin at 2 mg/day for -5-7 days of treatment
Study: NCT03488160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted CAR-T cells
Description: This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
Study: NCT01428817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 20mcg carbetocin, IV, over 1 minute following delivery of the fetal head.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 40mcg carbetocin, IV, over 1 minute following delivery of the fetal head.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 60mcg carbetocin, IV, over 1 minute following delivery of the fetal head.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
Study: NCT03653598

Intervention type: OTHER
Intervention: Atrial Fibrillation
Description: Data collection on Atrial Fibrillation
Study: NCT04749069

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Comparison of pain intensity rating scale
Description: Comparison of numerical pain intensity rating scale Comparison of faces pain rating scale Comparison of consumption of total amount of remifentanil

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Comparison of pain intensity rating scale
Description: Comparison of numerical pain intensity rating scale Comparison of faces pain rating scale Comparison of consumption of total amount of remifentanil
Study: NCT00838019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrabone administration of umbilical cord blood
Description: Single administration